PMID- 21151206
OWN - NLM
STAT- MEDLINE
DCOM- 20110519
LR  - 20220330
IS  - 1759-4782 (Electronic)
IS  - 1759-4774 (Linking)
VI  - 8
IP  - 2
DP  - 2011 Feb
TI  - Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.
PG  - 97-106
LID - 10.1038/nrclinonc.2010.196 [doi]
AB  - Tumor relapse and metastasis remain major obstacles for improving overall cancer 
      survival, which may be due at least in part to the existence of cancer stem cells 
      (CSCs). CSCs are characterized by tumorigenic properties and the ability to 
      self-renew, form differentiated progeny, and develop resistance to therapy. CSCs 
      use many of the same signaling pathways that are found in normal stem cells, such 
      as Wnt, Notch, and Hedgehog (Hh). The origin of CSCs is not fully understood, but 
      data suggest that they originate from normal stem or progenitor cells, or 
      possibly other cancer cells. Therapeutic targeting of both CSCs and bulk tumor 
      populations may provide a strategy to suppress tumor regrowth. Development of 
      agents that target critical steps in the Wnt, Notch, and Hh pathways will be 
      complicated by signaling cross-talk. The role that embryonic signaling pathways 
      play in the function of CSCs, the development of new anti-CSC therapeutic agents, 
      and the complexity of potential CSC signaling cross-talk are described in this 
      Review.
FAU - Takebe, Naoko
AU  - Takebe N
AD  - National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer 
      Therapy Evaluation Program, Investigational Drug Branch, EPN7131, 6130 Executive 
      Boulevard, Rockville, Bethesda, MD 20852, USA.
FAU - Harris, Pamela J
AU  - Harris PJ
FAU - Warren, Ronald Q
AU  - Warren RQ
FAU - Ivy, S Percy
AU  - Ivy SP
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20101214
PL  - England
TA  - Nat Rev Clin Oncol
JT  - Nature reviews. Clinical oncology
JID - 101500077
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hedgehog Proteins)
RN  - 0 (Receptors, Notch)
RN  - 0 (Wnt Proteins)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Hedgehog Proteins/*antagonists & inhibitors/metabolism
MH  - Humans
MH  - Neoplasms/metabolism/*prevention & control
MH  - Neoplastic Stem Cells/*drug effects
MH  - Receptors, Notch/*antagonists & inhibitors/metabolism
MH  - Signal Transduction/*drug effects
MH  - Wnt Proteins/*antagonists & inhibitors/metabolism
EDAT- 2010/12/15 06:00
MHDA- 2011/05/20 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/05/20 06:00 [medline]
AID - nrclinonc.2010.196 [pii]
AID - 10.1038/nrclinonc.2010.196 [doi]
PST - ppublish
SO  - Nat Rev Clin Oncol. 2011 Feb;8(2):97-106. doi: 10.1038/nrclinonc.2010.196. Epub 
      2010 Dec 14.